Call for Abstract

2nd International Conference on Biomarkers and Clinical Research, will be organized around the theme “Awareness of Biomarkers & Clinical Research”

BIOMARKERS CONGRESS-2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in BIOMARKERS CONGRESS-2020

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Biomarkers are molecules that signify an irregular process in your body and may be a sign of underlying disease or illness. Various types of molecules, such as DNA (genes), proteins, or hormones, can be used as biomarkers because they all mean something about your health. In response to cancer, biomarkers can be produced by the cancer tissue itself or by other cells in the body. These can be found in blood, stool urine, tumor or other tissues or body fluids. Biomarkers, in particular, are not restricted to cancer. Biomarkers are available for cardiac disease, multiple sclerosis, and many other diseases.

  • Track 1-1Imaging biomarkers
  • Track 1-2Sponge biomarkers
  • Track 1-3Regulatory validation
  • Track 1-4Protein phosphorylation biomarkers

Biomarkers and diagnostics play a vital role in enhancing the quality of human health outcomes and findings in clinical settings. In both preclinical and clinical settings, translational biomarkers and diagnostics can be implemented. It should seek to turn the findings into medical practice and practical health outcomes in fundamental research. This session will discuss the characteristics of acceptable translational biomarkers and the different approaches to their selection, including the latest trends and developments in translational biomarkers and diagnostics.

  • Track 2-1Transational biomarkers
  • Track 2-2Clinical diagnosis
  • Track 2-3C-reactive protein

The term "biomarker" refers to any of the molecules of your body that can be assessed for health assessment. Molecules can be extracted from your blood, body fluids, or tissue. Biomarker screening is a collection of tests that searches for these molecular indicators of health so physicians can prepare the best care. Often named "molecular testing" or "genetic testing" may be biomarker testing.

Many cancer biomarkers are used to determine the likelihood of a person developing cancer. For early detection (screening) and identification (diagnosis) of cancer, other cancer biomarkers are used. Biomarkers can be used to plan the best treatment after a diagnosis of cancer. If not on treatment, biomarkers may also be used to track outcomes of treatment or cancer growth. Biomarker assessments can be subdivided into three groups.


  • Track 3-1Translocational chromosomes
  • Track 3-2Gene mutation
  • Track 3-3Biochemical tests

Biomarkers used for clinical purposes are referred to as clinical biomarkers. Clinical biomarkers are an important and powerful way to understand the nature of many diseases and epidemiology, random clinical trials, drug screening, or diagnosis and prognosis of disease. It is defined as changes in cell or body fluid constituents, these clinical biomarkers offer the means for standardized classification of a disease and risk factors that can extend the basic information on the underlying pathogenesis of diseases.

The major medical biomarker research is conducted in the fields of drug discovery, pharmacogenomics, oncology, and diagnosis of disease. Biomarker categories in clinical trials are categorized into biomarkers for safety and efficacy.


  • Track 4-1Health biomarkers
  • Track 4-2Biomarkers effectiveness
  • Track 4-3Clinical trails of biomarkers in oncology
  • Track 4-4Clinical trials of biomarkers in diagnostics
  • Track 4-5Clinical trials of biomarkers in drug discovery
  • Track 4-6Clinical trials of biomarkers and pharmacogenomics

The spread of wearable digital technologies in the generation of big data in health care resulted in the appearance of a new type of medical information. We produce actionable insights into individuals ' biological environment, just as "normal" biomarkers, but are gathered by digital tools. Here is our summary of the significance of digital biomarkers and how they will be used in the near future.

X-ray or DNA test results are not part of the digital biomarker area

  • Track 5-1Structured solutions
  • Track 5-2Reliability of certain instruments
  • Track 5-3The calculation information may also be completely different
  • Track 5-4Privacy and regulatory issues in general are also a matter of concern

Neurological biomarkers are present only at or imperceptibly in the blood in the CSF (cerebrospinal fluid).The blood-brain barrier effectively protects the brain from toxic chemicals entering into the bloodstream. Unfortunately this barricade has also made brain chemistry unachievable for proper blood testing for diagnostic purposes. CSF may be used to test neurological biomarkers, but this involves an invasive and painful technique of lumbar puncture.

  • Track 6-1Personalized medicine and diagnostic in neuro science
  • Track 6-2Biomarker in neuro oncology brain tumor and brain damage
  • Track 6-3Biomarkers in central nervous system diseases
  • Track 6-4Biomarkers for early identification of neurological disorders

Biomarkers play a significant role in oncology used for risk assessment, differential diagnosis, evaluating the type of tumors, determining the prognosis and dose-response of the medication to treatment for detection purposes. The mechanism that indicates the presence of cancer in the body is conducted using instruments known as cancer biomarkers. Biomarkers have their application in various types of cancer, such as lung, melanoma, breast, colorectal, pancreas, and many more. Biochemically, biomarkers of cancer may include DNA, RNA, proteins, peptides, hormones, metabolites, and biological processes such as apoptosis, angiogenesis, or proliferation. Based on their medical use, there are three main types of cancer biomarkers: Prognostic, Predictive, pharmacodynamic markers.

  • Track 7-1Pharmacodynamic cancer biomarker
  • Track 7-2Predictive cancer biomarker
  • Track 7-3Biomarker for lung cancer
  • Track 7-4Colorectal cancer biomarker
  • Track 7-5Biomarker for gastric cancer
  • Track 7-6Biomarker for breast cancer
  • Track 7-7Biomarker for blood cancer

Biomarkers play a vital role in the prognosis and diagnosis of various cardiovascular and neurological diseases. Diseases that are deadly from ancient times can be treated and easily diagnosed using advances in biomarkers through different methods of diagnosis and imaging. In the diagnosis and prognosis of disease, cardiac biomarkers and neurobiomarkers brought a great revolution. In many other non-cancerous diseases, these biomarkers are also used.

  • Track 8-1Alzheimer’s disease
  • Track 8-2Cardiovascular diseases
  • Track 8-3Neurodegenerative diseases
  • Track 8-4Diabetes and behcet’s disease

Cardiovascular markers are biomarkers assessed to test cardiac function. They are often discussed in the context of myocardial infarction, but other conditions may result in an elevation of the heart marker level. When the heart is damaged or strained, Cardiac biomarkers are the elements that are released to the blood. A cardiac marker is used in patients with chest pain and suspected acute coronary syndrome (ACS) identification and risk stratification. Such markers include genes, proteins and hormones. Over the past 50 years, cardiac biomarkers have evolved as essential tools in cardiology, i.e. primary and secondary prevention, diagnosis and treatment of acute myocardial infarction (AMI), and the diagnosis and stratification of heart failure risk.

  • Track 9-1Cardiac troponin
  • Track 9-2CK, CK-MB, and myoglobin
  • Track 9-3Creatine kinase(it is not very specific)

Biomarkers that can control different immune system diseases such as autoimmunity, immunodeficiency, cancer, allergies, and infections are considered immunological biomarkers. This plays a very important role in the identification of biomarkers as the immune system interacts with all the other processes in the body. Immunological biomarkers including miRNA and serum Biomarkers can provide data about a body's immune response under normal or unusual conditions.

  • Track 10-1T cell assays(provide insight into the cells that actually target a beta cell)
  • Track 10-2Individualised signatures of biomarkers
  • Track 10-3• T cell profiles(classify at-risk patients in different categories that allow for personalized prediction, prevention and treatment approaches)

Genomic biomarkers are variations in the DNA code that are correlated with susceptibility to infection, disease expression and disease outcome, including therapeutic responses. Single nucleotide polymorphisms (SNPs; change in the DNA code when a single nucleotide is changed in the genome sequence) have been thoroughly studied in relation to CVD. The two classic complementary methods used to link genetic sequence variability to CVD risk are the linkage technique and the strategy of association. The primary objective of the Human Genome Project was to identify and develop such biomarkers for "personalized, preventive and predictive medicine."

  • Track 11-1Evolving array designs
  • Track 11-2Sophisticated understanding of genome architecture
  • Track 11-3Sophisticated understanding of genome architecture
  • Track 11-4Tissue biopsies

Biomarkers research in bipolar disorder is a new field with an expanding knowledge. It is associated with imbalances in various biological systems, including the immune system, neurotrophins, neuroendocrine axis, and oxidative stress. External molecules related to the pathophysiological mechanisms underlying the bipolar disorder may be a potential biomarker of the disease. Bipolar disorder is correlated with structural and functional changes in neuroimaging consistent with brain atrophy, including expansion of lateral ventricles and loss of prefrontal cortex and amygdala volumes. Bipolar disorder peripheral and neuroimaging findings may reflect neuroprogressive disease processes. It seems unlikely that a single candidate biomarker will tap the clinical and biological heterogeneity of bipolar disorder.

  • Track 12-1Bipolar effective
  • Track 12-2Brain mapping
  • Track 12-3Heterogeneity of bipolar disorder

Pharmacological research plays a crucial role in the development of cancer drugs. In especially in recent years, biomarker research studies has become an integral part of this process, specifically the use of pharmacological biomarkers in the development of targeted therapies and their translation into clinical practice. Clinical pharmacology is the science of drugs in human disease prevention, treatment, and control. A comprehensive understanding of clinical pharmacology principles is essential for any clinician to deliver optimal therapy to individual patients.

  • Track 13-1Predictive safety testing
  • Track 13-2PK biomarkers
  • Track 13-3PD proof-of-mechanism

Biomarkers have a tremendous potential to affect clinical trial success rate and identify new drug targets and advance diagnostic assays for early disease detection. The development of biomarkers originates in the phase of drug discovery and leads to clinical validation. In the target, biomarkers are used in the discovery and validation stage to identify and justify therapy targets. Biomarkers should have accurate qualities with an acceptable sensitivity and specificity representing a particular drug toxicity or therapeutic effect, a specific physiological response to a therapy, a pathological progression, or a physiological factor.

  • Track 14-1Drug discovery innovation and strategies
  • Track 14-2Biomarker in drug design
  • Track 14-3Phenotypical and genomic drug discovery
  • Track 14-4Medicine development in oncology and infectious diseases
  • Track 14-5Computational chemistry and informatics for drig discovery

Clinical research refers to all human (healthy or sick) research. It focuses on improving the knowledge of diseases, developing diagnostic and new treatments or medical devices to ensure better patient care. Clinical research is a branch of social security science that evaluates the well-being and efficacy of the approaches, tools, experimental components, and treatment regimes intended for human use.

By using prognostic biomarker, different types of reporting bias and publishing bias make the connection between CRP and prognosis among patients with stable coronary artery disease one of the most emerging innovative projects. Publication bias, statistical analytical protocols and study registration are one of the other measures that could help to improve the quality of biomarker research.


  • Track 15-1Obtain the consent of the research participants
  • Track 15-2Have the objective of increasing medical knowledge
  • Track 15-3Bioethics analytic
  • Track 15-4Protocols of biomarkers
  • Track 15-5Case studies

The identification and development of biomarkers for personalized, preventive and predictive medicine was a key thrust of the Human Genome Project. Genomics-related biomarkers test changes in the volume or composition of nucleic acids. Biomarkers dependent on DNA include differences in the number of copies, mutations (including polymorphisms, somatic mutations and other genetic variants) and epigenetic modifications.RNA expression-based biomarkers include quantification of mRNA, microRNA, and long non-coding RNA expression. Proteomics was widely used to study a wide range of medical fields including the development of drugs and the discovery of biomarkers.

  • Track 16-1Human genome project
  • Track 16-2Epigenetic modifications
  • Track 16-3Serum proteome
  • Track 16-4Revolutionise drug development process

In-house, clinical preliminary treatment can now and again be an organisational and functional weight. By outsourcing clinical preliminary dispersion halfway, pharmaceutical research associations will often have the ability to free up internal assets and, meanwhile, improve the safety and nature of their preliminary drug transmission.

  • Track 17-1IRT med management
  • Track 17-2Mass drug management
  • Track 17-3Forecasting
  • Track 17-4Stock management
  • Track 17-5Drug store services

The discovery of biomarkers requires highly confident identification of candidates for biomarkers with simultaneous quantitation information to indicate which proteins are changing in response to disease to a statistically relevant level. Because of natural medical or biological variability, a large number of samples need confirmation of candidate biomarkers identified in the discovery phase. The challenge is to develop a fast, targeted analysis method capable of analysing as many identified candidates as possible in minimally hundreds and potentially even thousands of samples.


  • Track 18-1Identify new medical biomarkers
  • Track 18-2Prioritize new protein targets for diagnostic testing of disease progression
  • Track 18-3Reaction to drug therapy

A reliable therapeutic biomarker would enable the identification of current management algorithms, ensure the elimination of pathogenic mechanisms prior to withdrawal from treatment, and reduce the frequency of unnecessary sustained therapy. As a result, various studies are underway to discover new biomarkers for various diseases, from cardiovascular disorders to autoimmune disorders and genetic disorders.

  • Track 19-1Ovarian cancer
  • Track 19-2Lung cancer
  • Track 19-3Endometrial cancer

Biomarker use and analytical tests continue to develop with more implementations and much more efficient sensitivity assays being introduced. These tests are powerful clinical tools that approach different therapeutic areas. Recent developments in biosensors to detect biomarkers in the treatment of cancer.

  • Track 20-1Oncology
  • Track 20-2Immunology
  • Track 20-3Endocrinology
  • Track 20-4Cardialogy